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Abstract 
      Despite recent improvements to current therapies and the emergence of novel agents to manage 
advanced non-small cell lung cancer (NSCLC), the patients′ overall survival remains poor. Re-challenging 
with first-line chemotherapy upon relapse is common in the management of small cell lung cancer but is not 
well reported for advanced NSCLC. NSCLC relapse has been attributed to acquired drug resistance, but 
the repopulation of sensitive clones may also play a role, in which case re-challenge may be appropriate. 
Here, we report the results of re-challenge with gemcitabine plus carboplatin in 22 patients from a single 
institution who had previously received gemcitabine plus platinum in the first-line setting and had either 
partial response or a progression-free interval of longer than 6 months. In this retrospective study, the 
charts of patients who underwent second-line chemotherapy for NSCLC in our cancer center between 
January 2005 and April 2010 were reviewed. All the patients who received a combination of gemcitabine 
and carboplatin for re-challenge were included in the study. These patients were offered second-line 
treatment on confirmation of clear radiological disease progression. The overall response rate was 15% 
and disease control rate was 75%. The median survival time was 10.4 months, with 46% of patients alive 
at 1 year. These results suggest that re-challenge chemotherapy should be considered in selected patients 
with radiological partial response or a progression-free survival of longer than 6 months to the initial 
therapy.
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Lung cancer is the most common cancer and is the leading 
cause of cancer-related mortality worldwide. An estimated 40,000 
new cases are diagnosed annually in the United Kingdom, and the 
5-year overall survival (OS) rate from the time of diagnosis is 10% to 
15% in the United States and Europe[1]. Non-small cell lung cancer 
(NSCLC) accounts for 75% to 80% of all lung cancer cases, of which 
adenocarcinoma (35% to 40%) and squamous cell carcinoma (30% 
to 35%) are the two most common subtypes[2]. Approximately 65% of 
patients present with locally advanced or metastatic disease and are 
not suitable for curative treatment[3]. 
Systemic anti-cancer therapy has been used in NSCLC to 
improve quality of life, disease control, and OS for lung cancer 
patients[4]. Platinum-based doublet chemotherapy is the mainstay 
first-line chemotherapy for advanced, non-adenocarcinoma NSCLC 
without an activating epidermal growth factor receptor (EGFR) 
mutation. In 2008, a meta-analysis incorporating 16 randomized 
trials and 2,714 cases confirmed that chemotherapy was associated 
with improved OS independent of factors such as age, performance 
status, and tumor histological subtype[5]. 
The majority of patients with advanced NSCLC treated with first-
line, platinum-based systemic anti-cancer therapy relapse or become 
refractory to the treatment. Only 4% to 6% of patients survive for 
more than 2 years[6-8]. The prognosis of patients with relapsed disease 
remains extremely poor, with limited treatment options. However, in 
patients with good performance status, systemic anti-cancer therapy 
can be considered. In this setting, the standard options include 
single agent cytotoxic therapy, small-molecule EGFR tyrosine kinase 
inhibitors (TKI), or treatment within the context of clinical trials, where 
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appropriate and available. Docetaxel has been shown to have an 
overall response rate of 7%, with a disease control rate of 50%. An 
improvement in progression-free survival (PFS) (11 weeks vs. 7 
weeks, P < 0.001) and OS (7 months vs. 5 months, P = 0.047) was 
noted in patients treated with docetaxel plus best supportive care 
compared with best supportive care alone[9]. Patients receiving 75 
mg/m2 of docetaxel had a 1-year survival rate of 37%[9]. Another 
phase III study compared docetaxel with pemetrexed in patients with 
recurrent NSCLC. A total of 571 patients were recruited in that study, 
and comparable clinical efficacy and 1-year survival rates of 30% 
were observed in both arms[10]. The study, however, demonstrated 
significantly increased toxicities in the docetaxel arm, with higher 
rates of neutropenia and neutropenic sepsis.  Further subset analysis 
showed better activity of pemetrexed in non-squamous tumors 
compared to docetaxel. Following the BR21 trial (a study coordinated 
by the National Cancer Institute of Canada Clinical Trials Group)[11] 
that compared erlotinib with best supportive care, erlotinib was used 
for second-line treatment of NSCLC. Despite the modest overall 
response rate of 9% (disease control rate = 47%), patients receiving 
erlotinib demonstrated significantly improved OS [7 months vs. 5 
months, hazard ratio (HR) = 0.70, P < 0.001], PFS (2.2 months 
vs. 1.8 months, P < 0.001), and quality of life compared with best 
supportive care[11]. Subsequently, the ISEL (Iressa Survival Evaluation 
in Lung Cancer) trial compared gefitinib, another TKI, with placebo 
and demonstrated a prolonged time-to-progression (TTP) in gefitinib 
arm (3.0 months vs. 2.6 months, P < 0.001); however, no significant 
difference in OS was observed in patients with relapsed NSCLC[12]. 
The overall outcome for patients treated with second-line systemic 
anti-cancer therapy, as assessed by OS and overall response rate, 
remains poor, and there is a clear need for new approaches to 
systemic anti-cancer therapy in this setting.
The response rate to systemic anti-cancer therapy in small 
cell lung cancer is high, and the drugs used in the first-line setting 
are often considered on relapse. Similarly, re-challenging with the 
same chemotherapy is a valid treatment strategy used in several 
advanced malignancies, after failure on first-line systemic anti-cancer 
therapy[13-16]. 
In this study, we report outcomes in patients with NSCLC who 
had a progression-free survival of longer than 6 months with first-
line gemcitabine plus platinum chemotherapy and who were re-
challenged with the same treatment regimen, i.e., gemcitabine-
platinum (rGC). All the patients in re-challenge setting received 
gemcitabine with carboplatin. We hypothesized that disease 
relapse is dominated by the re-growth of sensitive clones and that 
reintroduction of the first-line regimen may yield further response. 
Although re-challenge has been reported for NSCLC in an Asian 
population with good performance status with encouraging results[17], 
to our knowledge, we report the first series of patients re-challenged 
with a single regimen.
Patients and Methods
An existing data source in the Belfast Trust was used after 
approval by the hospital’s audit committee. The treatment offered was 
a part of the hospital guidelines and did not require ethics approval. 
All patients who participated in the study signed the generic consent 
form for treatment.
Patients
All patients who received rGC as second-line therapy for 
NSCLC between January 2005 and April 2010, following radiological 
evidence of disease progression, were included in the study if they 
had 1) a complete or partial response to first-line gemcitabine plus 
platinum-based treatment, 2) a progression-free interval longer than 
6 months, 3) an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0-2, and 4) at least one measurable lesion to 
evaluate response to treatment.
Treatment and response
Patients were treated with gemcitabine (1,250 mg/m2) on days 
1 and 8 along with carboplatin area under the curve (AUC)5 on 
day 1 in a 3-week cycle. No more than 6 cycles were offered to 
each patient. Overall response rate was determined according to 
modified Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria (version 1.1)[18]. Response was evaluated in all patients with 
computed tomography (CT) scan. Complete response (CR) was 
defined as complete disappearance of the tumor. Partial response 
(PR) was defined as less than a 30% decrease in the maximum 
diameter of measurable disease, in the absence of progression in 
non-target lesions or new disease. Progressive disease (PD) was 
defined as more than a 20% increase in the maximum diameter of 
measurable disease, or as evidence of new disease or progression in 
non-target lesions. Stable disease (SD) was defined as the disease 
that did not fit the category of PR or PD[18]. Disease control was 
defined as CR, PR, or SD. Treatment was stopped in patients with 
radiological evidence of disease progression according to the above-
mentioned criteria. 
Follow-up
While patients were treated, history taking, physical examination, 
and hematologic and biochemical tests were performed every 3 
weeks, and radiological investigations were performed at the end of 
the second and sixth cycles of treatment. All patients were followed 
up until death. Patients with PR or SD were followed up every 3 
months with clinical examination and repeat chest X-ray radiograph. 
If patients reported any symptomatic progression or chest X-ray 
radiograph demonstrated any evidence of progressive disease, CT 
scan of the chest, abdomen, and pelvis was performed to confirm 
evidence of progression. 
Statistical analyses
OS was calculated from the day second-line treatment was 
commenced until the date of death, and PFS was calculated from 
the day treatment was initiated to radiological or clinical disease 
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progression, both using MedCalc software (version 12.7.0, Ostend, 
Belgium). Survival curves were constructed using the Kaplan-
Meier method. Univariate and multivariate analyses were performed 
to evaluate factors that were predictive of response using SPSS 
software (version 19, Chicago, IL, USA). 
Results
Patient characteristics
The patients’ pre-treatment characteristics were balanced and 
similar to those of patients enrolled in clinical studies and treated in 
second-line setting in the context of NSCLC[9,10] (Table 1), with the 
exception of the predefined selection criteria. Twenty-two patients 
were recruited in the study based on the above-defined selection 
criteria, with a median age of 63 (range, 40-80 years); of those, 
18 (82%) received gemcitabine with carboplatin, and the remaining 
4 (18%) received gemcitabine with cisplatin in the first-line setting 
(median, 4 cycles; range, 3-6 cycles). Thirteen (59%) patients had a 
response to first-line chemotherapy, with 3 (14%) achieving CR and 
10 (45%) achieving PR. The median progression-free interval was 
12.7 months. Twelve (54%) patients relapsed with new metastatic 
disease, and 6 of them had sites of metastatic disease larger than 
3 cm. Of the remaining 10 patients, 5 had at least a 50% increase in 
the size of known metastatic disease, and 5 had locoregional relapse 
only.
Response and survival
The median follow-up time was 22 months. Nineteen patients 
died, all from disease progression. The response rate for rGC was 
15% [95% confidence interval (CI) = 0% to 16%], whereas the 
disease control rate was 75% (95% CI = 56% to 94%). The median 
OS was 10.4 months, and the 1-year OS rate was 46% (Figure 1). 
Patients with a performance status of 0-1 did better with rGC, with 
a median OS of 14 months and a 1-year OS rate of 60% (Figure 2). 
Factors predicting better OS with rGC included length of time from 
first-line treatment to the time of progression (HR = 0.9, 95% CI = 
0.9 to 1.0, P = 0.018) and ECOG performance status at the start 
of re-challenge (HR = 2.7, 95% CI = 1.3 to 5.7, P = 0.006), both in 
univariate and multivariate analyses (Tables 2 and 3). Interestingly, 
the response rate to first-line treatment was not predictive of OS or 
response to rGC. The median PFS was 5.6 months.
Toxicity
Sixteen (74%) patients undergoing rGC chemotherapy required 
a dose reduction. Four (18%) patients had to stop because of toxicity 
(predominately fatigue). One patient died within 30 days of finishing 
treatment; however, this death was due to disease progression.
Further treatments after second-line therapy
Following progression on rGC, 7 (32%) patients went on to 
have third-line treatment (3 were treated with docetaxel and 4 with 
erlotinib), with a median of 2 cycles (range, 1 to 3 cycles). The 
median survival of these 7 patients was 4.6 months from the start of 
third-line treatment.
Discussion
The present study demonstrates a valuable treatment strategy, 
albeit for a selected group of NSCLC patients. To our knowledge, 
only one study has been reported thus far adapting re-challenge 
as a treatment strategy in NSCLC. In that study, Nagano et al .[17] 
reported outcomes in a cohort of 28 patients treated with re-challenge 
chemotherapy for NSCLC and compared their outcomes with 38 
patients receiving docetaxel in second-line setting. All the 28 patients 
treated with re-challenge chemotherapy had a performance status 
of 0 or 1 and had shown previous response to systemic anti-cancer 
therapy. In Nagano study, PFS was not used as a selection criterion 
in the re-challenge group; some patients relapsed within 2 months 
of first-line treatment. A variety of treatment regimens were used in 
the first-line setting and, hence, on re-challenge. Of the 28 eligible 
patients, 10 (36%) were treated with vinca-alkaloid and cisplatin, 
3 (9%) with cisplatin and docetaxel, 2 (7%) with gemcitabine and 
vinorelbine, 1 (4%) with cisplatin and camptothecin, 1 (4%) with 
carboplatin and paclitaxel, 1 (4%) with gemcitabine and cisplatin, and 
Table 1. Baseline characteristics of 22 patients with 
non-small cell lung cancer (NSCLC)
PS, performance status; ECOG, Eastern Cooperative Oncology 
Group.
variable No. of patients (%)
Sex 
   Male 14 (64)
   Female   8 (36)
Smoking status
   Non-smoker 2 (9)
   Smoker 20 (91)
PS score (ECOG) 
   0   3 (14)
   1 12 (55)
   2   4 (18)
   3 1 (5)
   Undocumented 2 (9)
Clinical stage 
   IIIB   5 (23)
   IV 17 (77)
Histological subtype 
   Adenocarcinoma   6 (27)
   Squamous   9 (41)
   Adeno-squamous   3 (14)
   Unknown   4 (18)
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Figure 1. Overall survival 
curves for 22 patients with 
non-small cell lung cancer 
(NSCLC) from the start of re-
challenge chemotherapy with 
gemcitabine plus carboplatin 
(rGC).
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details of remaining first-line therapies were not provided. Our study 
is therefore the first describing the approach of standardized rGC in 
relapsed advanced NSCLC. Nagano et al. [17] reported that 9 (32%) 
patients underwent third-line chemotherapy and 4 (14%) underwent 
fourth-line chemotherapy. The reported median survival was 17 
months and the 1-year survival rate was 60%. The response rate 
was 29%, with a disease control rate of 75%. Median survival time 
was long in those with a disease-free interval longer than 6 months. 
These outcomes are comparable with the good performance status 
subgroup (0-1) in  our study.
Previous clinical trials in the second-line setting have shown 
a median survival of 7 to 8 months, with a 1-year OS rate of 30%. 
Response rates of 7% to 10% and disease control rates of 45% 
to 55% are typically seen[9-11]. However, clinical trials are generally 
guided by strict inclusion criteria, recruiting a better group of patients 
with good performance status and organ function reserve. In clinical 
practice, the results often tend to be worse than those reported in 
clinical trials. Our own unpublished audit of 94 patients with relapsed 
NSCLC treated in the second-line setting showed a median survival 
of 6 months and 1-year OS rate of 15%. Overall, our outcomes 
are inferior to those of the Nagano study, but the outcomes are 
comparable when only patients of performance status 0-1 are 
analyzed.
The selection criteria in our study may be argued to have elicited 
a population with slow-biology disease, making it more likely that 
disease stabilization or slow progression would have been achieved. 
However, before entry into the study, 6 (27%) of patients had bulky 
(greater than 3 cm) new metastatic disease, and 8 (36%) had disease 
that had increased by more than 50% since their previous imaging. 
Only 6 (27%) had small volume (less than 3 cm) new metastatic 
disease, and 2 (9%) had locoregional relapse that had grown less 
than 50% from previous imaging. 
Toxicity was difficult to define because the current study was 
retrospective in nature. Most patients required a dose reduction, 
and a significant number stopped due to toxicity, mainly fatigue. No 
patients died from chemotherapy-related toxicity. 
There are several proposed mechanisms of resistance to 
systemic anti-cancer therapy. Overexpression of metallothionein 
(MT)-related metabolic enzymes has been implicated in enzymatic 
inactivation of platinum drugs in NSCLC patients previously treated 
with cisplatin[19]. Likewise, inherent resistance to gemcitabine is 
associated with low deoxycytidine kinase (dCK) levels or high 
multidrug-resistant protein 5 (ABCC5)[20,21]. These studies imply 
that patients with low dCK levels can have resistance not only to 
Table 2. Univariate analysis to determine factors associated overall survival (OS) of patients who underwent re-
challenge chemotherapy with gemcitabine plus carboplatin (rGC)
RR, response rate; PS, performance status; HR, hazard ratio; CI, confidence interval.
Variate HR 95% CI P
Sex 1.5 0.6 to 3.8                 0.412
Smoking history 0.4 0.1 to 2.0                 0.253
Pathologic subtype 0.8 0.4 to 1.7                 0.586
RR for first-line chemotherapy 0.8 0.4 to 1.5                 0.454
Interval between first-line and second-line chemotherapy 0.9 0.9 to 1.0                 0.018
   >6 months 0.6 0.2 to 1.9                 0.441
   >12 months 0.5 0.2 to 1.3                 0.052
   >15 months 0.1 0.0 to 0.6                 0.007
PS at rGC 2.7 1.3 to 5.7                 0.006
Stage at rGC 0.8 0.1 to 7.7                 0.881
Third-line chemotherapy 0.8 0.3 to 2.0                 0.591
RR for rGC chemotherapy 1.9 0.2 to 5.2                 0.199
Table 3. Multivariate analysis to determine factors associated with OS of patients who underwent re-challenge 
chemotherapy
Variate HR 95% CI P
Time from first-line treatment to rGC 0.9 0.8 to 1.0 0.016
PS at rGC 3.6 1.4 to 9.1 0.008
Time from first-line treatment to rGC >15 months 0.1 0.0 to 0.5 0.009
Abbreviations as in Table 2.
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gemcitabine but also to pemetrexed and other cytotoxic agents[22]. 
These results were further reproduced in a clinical study which 
showed that the response to previous chemotherapy might predict 
the efficacy of second-line treatment with pemetrexed[23]. Acquired 
resistance to gemcitabine has a different mechanism and is 
associated with increased expression of ribonucleotide reductase M1 
(RRM1)[24]. In the current study, we showed that patients who once 
progressed on gemcitabine-platinum combination still demonstrated 
a response rate of 15%, suggesting that, theoretically, re-challenge 
can temporarily overcome the resistance mechanism.
Nevertheless, there remains a lack of clinical biomarkers 
to inform us about the potential outcome of patients treated with 
systemic anti-cancer therapy. In many studies, the expression of 
excision repair cross-complementation group 1 (ERCC1) predicted 
response rate in patients treated with cisplatin[25]. Olaussen et 
al.[26] demonstrated that patients with ERCC1-negative tumors who 
underwent 4 cycles of adjuvant cisplatin therapy had longer OS and 
disease-free survival compared with those with ERCC1-positive 
tumors. Similarly, the BRCA1 gene has also been implicated as a 
potential predictive marker for response to adjuvant platinum therapy 
in NSCLC[27]. RRM1 and RRM2 expression have been associated 
with reduced response rates in patients treated with gemcitabine 
plus docetaxel in the first-line setting in a phase III clinical study, 
whereas the overexpression of BRCA1 was associated with a better 
response to therapy[28,29]. Our study highlights the importance of 
further developing these biomarkers; indeed, there may be a group 
of patients who benefit from re-challenge with existing treatment 
options, and we may be able to achieve comparable and cost-
effective clinical efficacy for them to that observed with new treatment 
options.
There is strong body of evidence from both preclinical and 
clinical studies that specific biomarkers can potentially predict 
response to a particular type of chemotherapy, but no such 
biomarkers have been used so far in standard clinical practice. 
Although improved knowledge about the biology of NSCLC and 
the use of targeted agents has led to significant inroads in the 
management of this disease, there is a strong and unmet need 
to define biomarkers to inform clinicians about the choice of 
chemotherapy. In the absence of such robust biomarkers in standard 
practice, the current second-line management of NSCLC is highly 
dependent on clinical factors such as performance status and 
previous response to the treatment. 
Our study is retrospective in nature and only a small number 
of patients have been selected based on their good performance 
status and previous response to the rGC regimen, which may be 
a small proportion of all NSCLC patients. We, however, present a 
valid treatment option that can be considered in a selected group of 
patients.
Conclusions
Re-challenging with the same cytotoxic therapy is a valuable 
option in many malignancies, including small cell lung cancer, breast 
cancer, and ovarian cancer. Based on our results, we propose that, 
in selected group of patients, rCG should be considered a valid 
treatment strategy.
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